Stay updated on Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial

Sign up to get notified when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.2 in the Study Documents section; the rest of the page content and study information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-17T04:16:56.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A new site revision tag, Revision: v3.4.1, appears, with the previous tag Revision: v3.4.0 removed, and a government funding status notice is displayed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-10T01:16:09.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A top banner states that there is a lapse in government funding and information may not be up to date, and notes that the NIH Clinical Center is open with links to status updates.
    Difference
    0.3%
    Check dated 2026-02-02T21:36:05.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The changes are cosmetic UI updates: a glossary toggle is displayed, capitalization tweaks in QC-related labels, and a new revision version (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-26T20:45:34.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4 on the page. This appears to be an internal version update with no substantive changes to study details, eligibility criteria, enrollment, or outcomes.
    Difference
    0.0%
    Check dated 2026-01-19T15:43:37.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page adds an expanded Locations section with 19 state site entries (Alabama, Arizona, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, North Carolina, Oklahoma, Rhode Island, South Carolina, Texas) and updates the revision to v3.3.3; the HHS Vulnerability Disclosure section was removed.
    Difference
    2%
    Check dated 2025-12-22T01:38:11.000Z thumbnail image

Stay in the know with updates to Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.